Publications

Preclinical
AACR, Cancer Discovery
October 23, 2024
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo et al.
Preclinical
AACR-EORTC-NCI
October 23, 2024
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models
Madera et al.
Preclinical
World Bispecific Summit
September 4, 2024
Leveraging Azymetric to Optimally Format T-Cell Engagers and Bispecific ADCs
Preclinical
ACS
August 21, 2024
Design and selection of the novel camptothecin analog ZD06519: A payload optimized for antibody-drug conjugates
Brant et al.
Preclinical
Immuno-Oncology Summit
August 7, 2024
Building Differentiated & Next Generation T Cell Engagers to Improve Responses in Difficult-to-Treat Tumors.
Nicole Afacan
Preclinical
ACS
June 23, 2024
Development of a Novel TOPO1i ADC Platform: From Concept to Pipeline Application
Mark Petersen
Preclinical
PEGS
May 16, 2024
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
Dunja Urosev
Preclinical
PEGS
May 16, 2024
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and anti-tumor responses in hard-to-treat cancers
Newhook et al.
Preclinical
Festival of Biologics
April 17, 2024
Next Generation Trispecific T Cell Engagers (TriTCE) Designed to Improve Treatment Responses in Oncology
Genevieve Desjardins
Preclinical
AACR
April 10, 2024
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
Newhook et al.
Preclinical
AACR
April 10, 2024
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
Repenning et al.
Preclinical
AACR
April 8, 2024
Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates
Wong et al.